DEADLINE ALERT for RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2025
0mins
Source: Globenewswire
Class Action Lawsuits Announced: Law Offices of Howard G. Smith have filed class action lawsuits on behalf of shareholders from companies including Revance Therapeutics, Regeneron Pharmaceuticals, and BioAge Labs, with deadlines for lead plaintiff motions approaching in March 2025.
Allegations Against Companies: The lawsuits allege that these companies made false or misleading statements regarding their business operations, financial practices, and safety concerns, which misled investors about their true financial health and risks.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 742.00 USD with a low forecast of 627.00 USD and a high forecast of 870.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
5 Hold
1 Sell
Moderate Buy
Current: 741.920
Low
627.00
Averages
742.00
High
870.00
Current: 741.920
Low
627.00
Averages
742.00
High
870.00
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
